NCT02058017: OPB-51602 in Locally Advanced Nasopharyngeal Carcinoma Prior to Definitive Chemoradiotherapy |
|
|
| Terminated | 1 | 9 | RoW | OPB-51602, OPB-51602 OPB-51602 is an inhibitor of STAT3 phosphorylation developed by Otsuka Pharmaceuticals, Japan. | National University Hospital, Singapore, Otsuka Pharmaceutical Co., Ltd., Shin Nippon Biomedical Laboratories, Ltd. | Nasopharyngeal Carcinoma | 05/15 | 05/15 | | |
